Buprenorphine Sandoz
Transdermal patch for moderate chronic pain in adults
Quick facts about Buprenorphine Sandoz
Key takeaways about Buprenorphine Sandoz
- 7-day pain relief: Each patch provides continuous buprenorphine delivery through the skin for a full week, offering steady pain control
- Not for acute pain: Buprenorphine Sandoz is designed only for moderate, chronic pain — never for short-term or breakthrough pain
- Avoid heat exposure: External heat (heating pads, saunas, hot baths) increases drug absorption and can cause dangerous overdose
- Risk of serious interactions: Combining with benzodiazepines, alcohol, or other CNS depressants can cause life-threatening respiratory depression
- Ceiling effect: Buprenorphine has a partial agonist profile with a ceiling effect on respiratory depression, which may offer a wider safety margin compared to full opioid agonists
What Is Buprenorphine Sandoz and What Is It Used For?
Buprenorphine Sandoz is a transdermal patch that contains buprenorphine, a strong opioid painkiller. It is prescribed for adults to manage moderate, long-lasting (chronic) pain that requires continuous opioid therapy. The patch releases buprenorphine through the skin at a controlled rate over 7 days.
Buprenorphine belongs to a group of medicines known as opioid analgesics. Unlike full opioid agonists such as morphine or fentanyl, buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. This unique pharmacological profile means it provides effective pain relief while exhibiting a ceiling effect on respiratory depression, potentially making it a safer option among strong opioids for certain patient populations.
The transdermal delivery system is specifically engineered to release buprenorphine at a constant rate. The available strengths — 5, 10, 15, and 20 micrograms per hour — correspond to different patch sizes (6.25 cm², 12.5 cm², 18.75 cm², and 25 cm² respectively). Each patch contains a reservoir of buprenorphine that is gradually absorbed through the skin into the bloodstream over the course of seven days.
This medication is indicated for patients with chronic pain conditions such as osteoarthritis, neuropathic pain, chronic back pain, and other persistent pain states where non-opioid analgesics have proven insufficient. It is important to note that Buprenorphine Sandoz should not be used for acute or short-term pain, nor for pain that can be adequately managed with non-opioid analgesics.
Buprenorphine Sandoz patches are designed for once-weekly application. The patch provides continuous, steady-state plasma levels of buprenorphine, minimizing the peaks and troughs associated with oral opioid dosing. This can lead to more consistent pain control and potentially fewer side effects related to fluctuating blood levels.
Brand names and equivalents
Buprenorphine transdermal patches are marketed under several brand names worldwide, including Norspan, Buprenorphine STADA, Buprenorphine Teva, Buprenorphine G.L. Pharma, and Espranor (sublingual formulation). While these products share the same active ingredient, the specific formulation, patch technology, and excipients may differ between manufacturers. Always follow the prescribing instructions specific to the product you have been dispensed.
How does buprenorphine work?
Buprenorphine exerts its analgesic effects primarily by binding to mu-opioid receptors in the central nervous system. As a partial agonist, it activates these receptors but produces a submaximal response compared to full agonists. This means that above a certain dose, further increases do not proportionally increase the analgesic effect or the degree of respiratory depression — this is known as the ceiling effect.
Additionally, buprenorphine has a very high affinity for the mu-opioid receptor, meaning it binds tightly and is difficult to displace. This property can be clinically relevant: if a patient on buprenorphine requires treatment with a full opioid agonist (for example, during surgery or for acute severe pain), higher doses of the full agonist may be needed to overcome buprenorphine's receptor occupancy. Healthcare providers managing such situations should be experienced in opioid pharmacology.
What Should You Know Before Using Buprenorphine Sandoz?
Do not use Buprenorphine Sandoz if you are allergic to buprenorphine, have severe breathing problems, are taking MAO inhibitors, have myasthenia gravis, or have a history of alcohol withdrawal symptoms. Several conditions require special caution, including liver disease, fever, and concurrent use of CNS depressants.
Contraindications
There are specific situations where Buprenorphine Sandoz must not be used. These absolute contraindications are based on the potential for serious or life-threatening adverse effects:
- Allergy to buprenorphine or any other ingredient in the patch (see the contents section below)
- Severe respiratory problems — buprenorphine can further depress breathing
- Drug dependence or substance use disorder — the transdermal formulation is not indicated for opioid addiction treatment
- Current or recent (within 14 days) use of MAO inhibitors such as tranylcypromine, phenelzine, isocarboxazid, moclobemide, or linezolid
- Myasthenia gravis — a condition causing severe muscle weakness that may be worsened by opioids
- History of alcohol withdrawal symptoms such as agitation, anxiety, tremors, or sweating upon stopping alcohol consumption
Opioid medicines including buprenorphine can cause life-threatening respiratory depression. This risk is greatest during initiation of therapy or after dose increases. Patients, caregivers, and family members should be alert for signs of slow, shallow, or difficult breathing, especially during sleep. Seek emergency medical attention immediately if breathing becomes dangerously slow or stops.
Warnings and precautions
Speak to your doctor or pharmacist before using Buprenorphine Sandoz if any of the following apply to you:
- You have recently consumed large amounts of alcohol
- You suffer from seizures or convulsions
- You have severe headache or nausea after a head injury, or have raised intracranial pressure (the patch may worsen symptoms or mask the extent of a head injury)
- You feel dizzy or faint
- You have severe liver problems (hepatic impairment alters buprenorphine metabolism)
- You have a fever (elevated body temperature increases the rate of drug absorption from the patch)
- You have depression or other conditions treated with antidepressant medications (risk of serotonin syndrome when combined with certain antidepressants)
- You have recently had surgery
Tolerance, dependence and misuse
Buprenorphine is an opioid, and repeated use of opioid medicines can lead to tolerance (the drug becomes less effective over time), physical dependence (the body adapts and withdrawal symptoms occur upon abrupt discontinuation), and misuse or addiction (compulsive use despite harm). The risk of these outcomes may increase with higher doses and longer treatment duration.
You may be at greater risk of dependence or misuse if you or a family member has a history of substance use disorder, if you smoke, or if you have a history of mental health conditions such as depression, anxiety, or personality disorders. Your doctor should regularly assess whether continued opioid therapy is appropriate and discuss tapering or alternative treatments when possible.
Sleep-related breathing disorders
Buprenorphine Sandoz can cause sleep-related breathing disorders including sleep apnea (pauses in breathing during sleep) and sleep-related hypoxemia (low blood oxygen levels during sleep). Symptoms may include breathing pauses observed by others, waking up gasping for air, difficulty maintaining sleep, or excessive daytime sleepiness. If you or another person observe these symptoms, contact your doctor, who may consider reducing your dose.
Pregnancy and breastfeeding
Do not use Buprenorphine Sandoz if you are pregnant, planning to become pregnant, or breastfeeding. Opioid use during pregnancy can cause neonatal opioid withdrawal syndrome in the newborn, which can manifest as high-pitched crying, irritability, tremors, feeding difficulties, sweating, and failure to gain weight. If you discover you are pregnant while using the patch, contact your doctor immediately for guidance on safe discontinuation.
Driving and operating machinery
Buprenorphine Sandoz can affect your reaction time and mental alertness, particularly at the start of treatment, after dose changes, or when taken with alcohol or sedatives. If you experience dizziness, drowsiness, or blurred vision, do not drive or operate machinery while using the patch and for at least 24 hours after patch removal.
Children and adolescents
Buprenorphine Sandoz transdermal patches are not recommended for patients under 18 years of age. Safety and efficacy have not been established in the pediatric population for this formulation.
How Does Buprenorphine Sandoz Interact with Other Drugs?
Buprenorphine Sandoz has clinically significant interactions with MAO inhibitors (contraindicated), benzodiazepines and other sedatives (risk of coma and death), certain antidepressants (risk of serotonin syndrome), and enzyme-inducing medications (reduced efficacy). Always inform your doctor of all medicines you are taking.
Drug interactions can alter how Buprenorphine Sandoz works or increase the risk of serious side effects. Some interactions are life-threatening and represent absolute contraindications, while others require dose adjustments, close monitoring, or avoidance. The table below summarizes the most important interactions.
Major interactions
| Drug / Class | Risk | Action |
|---|---|---|
| MAO inhibitors (tranylcypromine, phenelzine, isocarboxazid, moclobemide, linezolid) | Potentially fatal interaction; unpredictable effects on blood pressure and CNS | Contraindicated. Do not use within 14 days of MAO inhibitor therapy |
| Benzodiazepines (diazepam, alprazolam, lorazepam, etc.) and related sedatives | Profound sedation, respiratory depression, coma, death | Avoid if possible. If co-prescribed, use lowest doses and shortest duration. Monitor closely |
| Alcohol | Enhanced CNS depression; impaired judgement and reaction time | Avoid. Do not drink alcohol during treatment |
| Other opioids (morphine, codeine, tramadol, fentanyl) | Additive respiratory depression; buprenorphine may reduce efficacy of full agonists | Use with extreme caution. Specialist guidance required |
| Serotonergic antidepressants (SSRIs, SNRIs, tricyclics) | Serotonin syndrome: agitation, hallucinations, high fever, muscle rigidity, rapid heart rate | Monitor carefully. Seek immediate medical attention if symptoms occur |
Moderate interactions
| Drug / Class | Effect | Recommendation |
|---|---|---|
| Enzyme inducers (rifampicin, phenobarbital, phenytoin, carbamazepine) | Increased metabolism of buprenorphine; reduced analgesic effect | Monitor pain control; dose adjustment may be needed |
| Gabapentin / Pregabalin | Additive CNS depression; increased sedation and respiratory risk | Use lower doses; monitor for sedation and respiratory depression |
| Antihistamines (sedating types), antipsychotics | Enhanced sedation, drowsiness, impaired cognition | Monitor for excessive sedation; consider dose reduction |
| Antihypertensives (e.g. clonidine) | Additive hypotensive and sedative effects | Monitor blood pressure and alertness |
| Muscle relaxants | Increased sedation and risk of respiratory depression | Use with caution; monitor closely |
What Is the Correct Dosage of Buprenorphine Sandoz?
Buprenorphine Sandoz is applied as one patch every 7 days. Treatment typically starts with the 5 µg/h patch, and the dose may be increased by your doctor after at least 3 days. The maximum recommended dose is 40 µg/h (two 20 µg/h patches). Never cut, divide, or apply more patches than prescribed.
Always use this medicine exactly as your doctor has told you. Your doctor will determine the most appropriate strength based on your current pain level, previous opioid use, and individual response. Before starting treatment and at regular intervals during treatment, your doctor will discuss treatment goals, duration, and when and how to discontinue therapy.
Adults and elderly patients
Standard dosing for adults
- Starting dose: One patch of 5 µg/h, applied to the skin and changed every 7 days
- Dose titration: After at least 3 days at the current dose (when full effect is reached), your doctor may increase the patch strength
- Maximum dose: 40 µg/h (no more than two patches at the same time)
- Change schedule: Replace the patch every 7 days, preferably at the same time of day
- Application site: Rotate between upper arm, upper chest, upper back, or side of chest
Available patch strengths
- 5 µg/h — 6.25 cm² patch containing 5 mg buprenorphine
- 10 µg/h — 12.5 cm² patch containing 10 mg buprenorphine
- 15 µg/h — 18.75 cm² patch containing 15 mg buprenorphine
- 20 µg/h — 25 cm² patch containing 20 mg buprenorphine
Elderly patients generally do not require dose adjustments, but your doctor will start with the lowest effective dose and titrate cautiously. Patients with liver disease may experience altered drug effects and require closer monitoring.
Children and adolescents
Buprenorphine Sandoz transdermal patches should not be used in patients under 18 years of age. There is insufficient evidence to support safe and effective use in the pediatric population.
How to apply the patch
Correct application technique is essential for optimal drug delivery and to minimize application site reactions:
- Choose the application site: Select a flat, non-irritated area of skin on the outer upper arm, upper chest, upper back, or side of the chest. If hair is present, clip it with scissors — do not shave, as this may irritate the skin.
- Prepare the skin: Wash the area with cool or lukewarm water only. Do not use soap, alcohol, oils, lotions, or other cleansing products. Allow the skin to dry completely. Wait until skin is cool after a hot bath or shower.
- Open the sachet: Tear along the marked line immediately before use. Check that the sachet seal is intact. Remove the patch.
- Apply the patch: Peel off one half of the protective film, press the sticky side onto the skin, then remove the remaining backing. Press the entire patch firmly with the palm of your hand for 30 seconds, paying special attention to the edges.
- Record the date and time: Note when you applied the patch so you can change it at the same time 7 days later.
You can shower, bathe, and swim while wearing the patch. If edges begin to peel, secure them with medical adhesive tape. Do not expose the patch to external heat sources (heating pads, electric blankets, heat lamps, saunas, hot baths, heated waterbeds), as heat significantly increases the rate of drug absorption. If you have a fever, the absorption rate may also increase — inform your doctor.
Missed dose
If you forget to change your patch on the scheduled day, apply a new patch as soon as you remember. Note the new date, as your regular change day may now be different. If you are significantly delayed, your pain may return. Do not apply extra patches to compensate for a missed dose. Contact your doctor if you are unsure.
Overdose
If you suspect an overdose — for example, if more patches than prescribed have been applied, or if a child has been accidentally exposed to a patch — remove all patches immediately and seek emergency medical attention. Signs of overdose may include extreme drowsiness, nausea, slow or shallow breathing, loss of consciousness, and pinpoint pupils. Bring this information leaflet and any remaining patches when seeking medical help.
Opioid overdose can be rapidly fatal. If someone wearing buprenorphine patches becomes unresponsive or stops breathing, call emergency services immediately. If naloxone is available, administer it according to instructions, but be aware that buprenorphine's high receptor affinity may require higher or repeated doses of naloxone compared to other opioids.
Stopping treatment
Do not stop using Buprenorphine Sandoz without consulting your doctor. Abrupt discontinuation after prolonged use can cause withdrawal symptoms including agitation, anxiety, nervousness, tremor, hyperactivity, insomnia, and digestive disturbances. Your doctor will guide you on how to gradually reduce the dose.
The analgesic effect persists for some time after patch removal. Do not start any other strong opioid painkiller until at least 24 hours after the last patch has been removed.
What Are the Side Effects of Buprenorphine Sandoz?
The most common side effects include headache, dizziness, drowsiness, constipation, nausea, vomiting, itching, and skin reactions at the application site. Most side effects are mild and often improve after the first week. Serious side effects include respiratory depression, severe allergic reactions, and dependence.
Like all medicines, Buprenorphine Sandoz can cause side effects, although not everyone experiences them. Serious side effects are similar to those seen with other strong opioid painkillers and include breathing difficulties and low blood pressure. This medicine can cause allergic reactions — though serious allergic reactions are rare. Remove the patch and seek immediate medical attention if you develop wheezing, difficulty breathing, swelling of the face or eyelids, or widespread rash with itching.
Very Common
- Headache, dizziness, drowsiness
- Constipation, nausea, vomiting
- Itching (pruritus), skin redness
- Rash, itching, redness, inflammation or swelling at the patch site
Common
- Loss of appetite
- Confusion, depression, anxiety, insomnia, nervousness, tremor
- Shortness of breath
- Abdominal pain or discomfort, diarrhea, indigestion, dry mouth
- Sweating, eczema, skin rash
- Fatigue, feeling of unusual weakness, muscle weakness, edema (swollen hands, ankles or feet)
Uncommon
- Mood swings, restlessness, agitation, euphoria, hallucinations, nightmares, decreased libido, aggression
- Taste disturbance, decreased sensitivity, tingling or numbness, memory loss, migraine, fainting, concentration difficulties
- Dry eyes, blurred vision, ringing in ears, vertigo
- High or low blood pressure, chest pain, rapid heartbeat, flushing
- Cough, hiccups, wheezing
- Flatulence, weight loss, dry skin, muscle spasms
- Difficulty urinating, urinary disorders, involuntary urination
- Fever, increased accident rate (e.g. falls)
- Withdrawal symptoms (agitation, anxiety, sweating, tremor)
Rare and Very Rare
- Angina (chest pain related to heart disease)
- Psychotic disorder, balance disturbances
- Facial or eyelid swelling, constriction of pupils
- Breathing difficulties, worsening of asthma, hyperventilation
- Faintness especially when standing, speech difficulties, difficulty swallowing, intestinal obstruction
- Local allergic reactions with marked swelling
- Decreased erection, impaired sexual function
- Seizures, convulsions (frequency not known)
- Intestinal wall inflammation (frequency not known)
- Neonatal withdrawal syndrome in newborns of mothers treated during pregnancy (frequency not known)
- Contact dermatitis, skin discoloration (frequency not known)
If you need blood tests while using Buprenorphine Sandoz, remind your doctor that you are using this medication. Buprenorphine can affect liver function, which may influence the results of certain blood tests.
How Should You Store Buprenorphine Sandoz?
Store below 25°C in the original sachet until use. Keep out of sight and reach of children — even used patches contain residual buprenorphine that can be harmful or fatal. Fold used patches sticky side inward and dispose of safely.
Proper storage and disposal of Buprenorphine Sandoz patches is critical for safety, particularly in households with children or pets. Even after use, a significant amount of active substance remains in the patch.
- Store at or below 25°C (77°F)
- Keep in the original sealed sachet until ready to use
- Do not use if the sachet seal is broken or damaged
- Check the expiry date (EXP) on the carton and sachet — do not use after this date
- Keep in a secure place where other people, especially children, cannot access it — accidental exposure can be fatal
Disposal of used patches
After removal, fold the used patch in half with the adhesive side inward so it sticks to itself. Place it in the empty sachet and dispose of it safely, ensuring that children and pets cannot reach it. Do not flush patches down the toilet or discard them with household waste. Return unused or expired patches to a pharmacy for safe disposal to protect the environment.
What Does Buprenorphine Sandoz Contain?
The active substance is buprenorphine, available in four strengths (5, 10, 15, and 20 µg/h). The patch consists of multiple layers including an adhesive matrix containing the drug, a separating film, a backing layer, and a removable protective liner.
Active substance
- Buprenorphine Sandoz 5 µg/h: 6.25 cm² patch containing 5 mg buprenorphine
- Buprenorphine Sandoz 10 µg/h: 12.5 cm² patch containing 10 mg buprenorphine
- Buprenorphine Sandoz 15 µg/h: 18.75 cm² patch containing 15 mg buprenorphine
- Buprenorphine Sandoz 20 µg/h: 25 cm² patch containing 20 mg buprenorphine
Other ingredients (excipients)
- Protective liner (removed before application): Siliconized polyethylene terephthalate (PET) film
- Adhesive layer (containing buprenorphine): Levulinic acid, oleyl oleate, povidone K90, acrylic acid-butyl acrylate-2-(ethylhexyl) acrylate-vinyl acetate copolymer (5:15:75:5)
- Separating film: Polyethylene terephthalate (PET) film
- Adhesive layer (without buprenorphine): Acrylate adhesive
- Backing layer: Polyurethane film with printed text
Appearance and pack sizes
Buprenorphine Sandoz patches are pale yellowish-brown, rectangular with rounded corners, marked with the strength (e.g. "Buprenorphinum 5 µg/h"). Each patch is individually sealed in a child-resistant sachet. Packs contain 1, 2, 3, 4, 5, 8, 10, 12, or 20 patches. Not all pack sizes may be marketed in your country.
Frequently Asked Questions About Buprenorphine Sandoz
Medical References and Sources
This article is based on current medical research and international prescribing information. All claims are supported by scientific evidence from peer-reviewed and regulatory sources.
- European Medicines Agency (EMA). "Summary of Product Characteristics: Buprenorphine transdermal patches." EMA Product Information European regulatory prescribing information for buprenorphine transdermal patches.
- World Health Organization (WHO) (2023). "WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents." WHO Guidelines International guidelines for pain management including opioid use.
- British National Formulary (BNF). "Buprenorphine: Drug Monograph." BNF Buprenorphine Comprehensive prescribing information from the UK National Formulary.
- U.S. Food and Drug Administration (FDA). "Butrans (Buprenorphine) Transdermal System: Prescribing Information." FDA Prescribing Information US regulatory prescribing information for buprenorphine transdermal system.
- Pergolizzi J, et al. (2010). "The role of transdermal buprenorphine in the treatment of chronic noncancer pain." Therapeutics and Clinical Risk Management. 6:559-571. Peer-reviewed analysis of buprenorphine's role in chronic pain management.
- Coe MA, et al. (2019). "Ceiling effects of buprenorphine: A review of the evidence." Pharmacology Research & Perspectives. 7(6):e00537. Review of the ceiling effect on respiratory depression, a key safety feature of buprenorphine.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. Prescribing information is sourced from EMA and FDA regulatory approvals. Clinical evidence is drawn from randomized controlled trials and systematic reviews.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources, EMA SmPCs, and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research or regulatory changes emerge.
Corrections Policy
Any errors are corrected immediately with transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in pharmacology, pain medicine, and clinical medicine.